Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02436057 · ClinicalTrials.gov registry record · NA

Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform

A NA study of Constipation and Gastroesophageal Reflux, sponsored by Cedars-Sinai Medical Center.

Completed
Registry status
NA
Development phase
255
Enrollment target
3
Study locations

NCT02436057: Completed NA study of Constipation and Gastroesophageal Reflux, sponsored by Cedars-Sinai Medical Center.

NCT02436057 is a NA study of Constipation and Gastroesophageal Reflux that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 255 participants, above the 201-participant average among 54 other Constipation trials with a reported enrollment target (27% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02436057, a NA study of Constipation and Gastroesophageal Reflux, has completed, sponsored by Cedars-Sinai Medical Center.

COMPLETED
Registry status
NA
Development phase
255 participants
Enrollment target
3
Study locations

Study Summary

Through a four-year grant awarded to the University of California at Los Angeles in 2009, Dr. Brennan Spiegel served as a principal investigator (PI) for a project to develop and initially validate a bank of items to assess gastrointestinal (GI) symptoms for the National Institutes of Health's (NIH's) Patient Reported Outcomes Measurement Information System (PROMIS). By the end of the grant period in July 2013, the project team had successfully developed and initially validated eight scales measuring the most common GI symptoms. Afterwards, Dr. Spiegel's PROMIS team joined forces with the UCLA Computing Technology Research Laboratory (CTRL) and the University of Michigan Center for Healthcare Communication Research to develop the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) algorithm which is delivered via My GI Health, an open--source Internet based patient-provider portal (P3) designed to enhance the delivery of GI health care (www.MyGIHealth.org). Through My GI Health and AEGIS, patients are able to complete PROMIS GI symptom measures and provide additional information about their GI symptoms and histories from computers, tablets or smart phones without the constraints of physical locale. This information is condensed into a GI PROMIS scores report and initial GI history that patients' providers can review prior to or concurrent with seeing the patient. The report, which can be incorporated into the electronic health record (EHR), helps busy clinicians to quickly understand the patient's complaints, document their symptoms and GI history, and leaves more time for conversation with the patient. Beyond focusing their interaction, My GI Health also supports both the clinician and patient with an individualized "educational prescription" which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments also contained within the website. The prescription is initially created by the website based o

Primary Outcome

The Consumer Assessment of Health Providers \& Systems Clinician and Group Survey - Adult Visit Questionnaire 2.0 (CG-CAHPS) will be used to assess patient satisfaction.

Interventions

  • OTHER AEGIS (Automated Evaluation of Gastrointestinal Symptoms)

Study Locations (3)

California

  • Cedars-Sinai Medical Center - Los Angeles
  • West Los Angeles VA Medical Center - Los Angeles

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2014-07
Est. Completion 2015-12
Phase NA
Cedars-Sinai Medical Center

339 total trials

What the finished NCT02436057 record still lists

NCT02436057 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 201-participant average among 54 other Constipation trials with a reported enrollment target (27% higher).

The record links to 7 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which AEGIS (Automated Evaluation of Gastrointestinal Symptoms) is the first listed.

NCT02436057 reports a single indexed study location in California, Michigan.

Frequently Asked Questions

What is clinical trial NCT02436057 about?

NCT02436057 is a clinical study titled "Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform". Through a four-year grant awarded to the University of California at Los Angeles in 2009, Dr. Brennan Spiegel served as a principal investigator (PI) for a project to develop and initially validate a bank of items to assess gastrointestinal (GI) symptoms for the National Institutes of Health's (NIH'...

What is the current status of trial NCT02436057?

This trial is currently completed. It is a NA study. The enrollment target is 255 participants. The study started on 2014-07. Estimated completion is 2015-12.

What conditions does trial NCT02436057 study?

This clinical trial studies the following conditions: Constipation, Gastroesophageal Reflux, Diarrhea, Fecal Incontinence, Abdominal Pain.

What interventions are being tested in trial NCT02436057?

The interventions under investigation include: AEGIS (Automated Evaluation of Gastrointestinal Symptoms) (OTHER).

Who is sponsoring clinical trial NCT02436057?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02436057 being conducted?

This trial has 3 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Constipation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02436057's enrollment target sits among peer trials

255 8th of 54 higher than 47 of 54 other Constipation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04623424 · 255 participants

    Intestinal Microbiota in Stem Cell Transplant Transplant Admission

  • NCT05114798 · 255 participants · NA

    Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

  • NCT05336188 · 255 participants · Phase 2

    Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder

  • NCT05486637 · 255 participants · Early Phase 1

    Vocal Emotion Communication With Cochlear Implants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02436057, the US trial registry maintained by the National Library of Medicine. NCT02436057 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.